NO992384L - Multivalente salter av pyridostigmin og relaterte forbindelser - Google Patents

Multivalente salter av pyridostigmin og relaterte forbindelser

Info

Publication number
NO992384L
NO992384L NO992384A NO992384A NO992384L NO 992384 L NO992384 L NO 992384L NO 992384 A NO992384 A NO 992384A NO 992384 A NO992384 A NO 992384A NO 992384 L NO992384 L NO 992384L
Authority
NO
Norway
Prior art keywords
anions
modifications
ring
pyridostigmine
related compounds
Prior art date
Application number
NO992384A
Other languages
English (en)
Other versions
NO992384D0 (no
Inventor
Colin D Granger
Robert Orr
Kandasamy Ramasamy
Original Assignee
Icn Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icn Pharmaceuticals filed Critical Icn Pharmaceuticals
Publication of NO992384D0 publication Critical patent/NO992384D0/no
Publication of NO992384L publication Critical patent/NO992384L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Et kvatemært ammonium-kolinergt middel komplekseres med et multivalent anion eller med flere monovalente anionen Komplekset kan administreres peroralt til en pasient for å behandle smerte eller for andre formål. En rekke modifikasjoner kan være aktuelle , herunder modifiseringer av forbindelsens ringstruktur, samt substitusjon og funksjonalisering av ringen. Andre aktuelle modifikasjoner innbefatter anvendelsen av ulike anioner, inklusivt forskjellige monovalente og polyvalente anioner, og både organiske og uorganiske anioner. Forbindelsene har anvendelse som kolinerge midler, spesielt ved behandlingen av myastenia gråvis, brystsmerte og karpaltunnelsyndrom.
NO992384A 1996-11-19 1999-05-18 Multivalente salter av pyridostigmin og relaterte forbindelser NO992384L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3118696P 1996-11-19 1996-11-19
PCT/US1997/020509 WO1998022458A1 (en) 1996-11-19 1997-11-10 Multivalent salts of pyridostigmine and related compounds

Publications (2)

Publication Number Publication Date
NO992384D0 NO992384D0 (no) 1999-05-18
NO992384L true NO992384L (no) 1999-07-16

Family

ID=21858083

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992384A NO992384L (no) 1996-11-19 1999-05-18 Multivalente salter av pyridostigmin og relaterte forbindelser

Country Status (17)

Country Link
US (1) US6211201B1 (no)
EP (1) EP0941224A4 (no)
JP (1) JP2001505561A (no)
KR (1) KR20000069028A (no)
CN (1) CN1237969A (no)
AU (1) AU717740B2 (no)
BR (1) BR9713112A (no)
CA (1) CA2271786A1 (no)
CZ (1) CZ172799A3 (no)
HU (1) HUP9904040A3 (no)
IL (1) IL129619A0 (no)
NO (1) NO992384L (no)
NZ (1) NZ335419A (no)
PL (1) PL333414A1 (no)
SI (1) SI20018A (no)
SK (1) SK64399A3 (no)
WO (1) WO1998022458A1 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092003A2 (en) * 2001-05-11 2002-11-21 Bacaner Marvin B Novel therapeutical quaternary ammonium compositions
UA80841C2 (en) * 2002-10-07 2007-11-12 Univ California Fatty acid amide hydrolase inhibitors, pharmaceutical composition (variants) and method to treat appetite disorders, glaucoma, pain, and related neurological disorders (variants)
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
AU2015217221A1 (en) 2014-02-13 2016-08-11 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
US9994600B2 (en) 2014-07-02 2018-06-12 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
CN107854428A (zh) * 2016-12-20 2018-03-30 成都医学院 一种溴吡斯的明糖浆剂及其制备方法
WO2019139919A1 (en) 2018-01-09 2019-07-18 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof
CN113277961B (zh) * 2021-04-09 2023-05-09 深圳市新浩瑞医药科技有限公司 一种溴新斯的明的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692530A (en) * 1967-03-07 1987-09-08 The United States Of America As Represented By The Secretary Of The Army Chemical agents
US4686293A (en) * 1967-05-29 1987-08-11 The United States Of America As Represented By The Secretary Of The Army Chemical agents
US4672120A (en) * 1967-07-03 1987-06-09 The United States Of America As Represented By The Secretary Of The Army Chemical agents
US4246416A (en) * 1967-12-01 1981-01-20 The United States Of America As Represented By The Secretary Of The Army Chemical agents
US4677222A (en) * 1968-01-22 1987-06-30 The United States Of America As Represented By The Secretary Of The Army Ketobenzylcarbamates
US5534623A (en) * 1993-01-21 1996-07-09 Du Pont (Uk) Limited Process for preparing a polyunsaturated diazonium compounds

Also Published As

Publication number Publication date
IL129619A0 (en) 2000-02-29
NO992384D0 (no) 1999-05-18
SK64399A3 (en) 2000-05-16
BR9713112A (pt) 2000-04-11
CN1237969A (zh) 1999-12-08
NZ335419A (en) 2000-05-26
AU6236798A (en) 1998-06-10
HUP9904040A2 (hu) 2000-05-28
AU717740B2 (en) 2000-03-30
CA2271786A1 (en) 1998-05-28
US6211201B1 (en) 2001-04-03
KR20000069028A (ko) 2000-11-25
JP2001505561A (ja) 2001-04-24
CZ172799A3 (cs) 1999-10-13
EP0941224A4 (en) 2000-01-12
HUP9904040A3 (en) 2000-09-28
PL333414A1 (en) 1999-12-06
SI20018A (sl) 2000-02-29
WO1998022458A1 (en) 1998-05-28
EP0941224A1 (en) 1999-09-15

Similar Documents

Publication Publication Date Title
FI972781A0 (fi) Menetelmät ja koostumukset allergisen nuhan ja muiden sairauksien hoitamiseksi käyttäen dekarboetokyloratadieeniä
BR0012590A (pt) Composto, processo para a preparação do mesmo, formulação farmacêutica, uso de um composto, e, métodos para tratamento ou profilaxia de dor ou desconforto, e para tratamento ou profilaxia de dor neuropática ou central
NO992384L (no) Multivalente salter av pyridostigmin og relaterte forbindelser
BR9714677A (pt) "enantiÈmeros 3-piridila e seu uso como analgésicos"
NO20006604L (no) Fremgangsmåter og transdermale sammensetninger for lindring av smerte
Wells et al. The brief psychotherapies: A selective overview
EP0824917A3 (en) Use of a serotonin 5-HTlf agonist in the manufacture of a medicament for treating or ameliorating the symptoms of common cold or allergic rhinitis
NO307570B1 (no) Inklusjonskomplekser oppnådd fra nimesulidalkali- og nimesulidjordalkalisalter og cyklodekstriner eller cyklodekstrinderivater, samt farmasøytisk preparat inneholdende nevnte inklusjonskompleks og fremgangsmåte for å fremstille samme
BR9815098A (pt) Uso de mirtazapina ou de um seu sal farmaceuticamente aceitável, e, processo para o tratamento de apnéias do sono em um aninal.
BR9811473A (pt) Infecção por rinovìrus inibida por óxido nìtrico
BR9809519A (pt) Sal, processo para fabricação e uso do mesmo, formulação farmacêutica, e, processo para prevenção ou tratamento de distúrbios cns e perturbações médicas relacionadas
KR980000445A (ko) 인식 증강 방법
WO1998022458B1 (en) Multivalent salts of pyridostigmine and related compounds
FI892596A0 (fi) Nya kondenserade diazepinoner och foerfarande foer deras framstaellning samt dessa foereningar innehaollande laekemedel.
KR930002322A (ko) 피라졸 유도체
AU3360000A (en) Use of 4-amino pyridine for treatment of peripheral neuropathies
BR9708922A (pt) Piridil-e pirimidil-piperazinas no tratamento de doenças causadas por substâncias usadas em excesso
Ellis et al. The atropine-fast nicotine stimulation of the rabbit's intestine and of the muscularis mucosae of the dog's intestine
NO975790L (no) Anvendelse av allylaminderivater slik som terbinafin, i fremstillingen av et medikament for behandling av helikobacterpylori-infeksjonsassosierte sykdommer
SE8804640D0 (sv) Medicament comprising cyclolinopeptide a
Uchida Clinical efficacy of topical lomefloxacin(NY-198) in bacterial infections of the external eye.
Lewis et al. Use of convalescent serum in the prevention of chickenpox
RU94044455A (ru) Средство для усиления функции макрофага и лечения человека с ослабленным иммунитетом
Burningham et al. A clinical update on fungal disease of human skin
FATAHI et al. COMPARISON OF 7 DAYS VERSUS 14 DAYS TREATMENT WITH CLARITHROMYCIN, AMOX1CILINAND OMEPRAZOLE FOR ERADICATION OF HELICOBACTER PYLORI

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application